Stratec, DE000STRA555

mwb research downgrades Stratec stock as execution risks rise in 2026

Published on 10/08/2026 at 18:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue rose 2.40 percent to EUR 59.10 million on August 14, 2026. Stratec stock costs EUR 22.03 on October 8, 2026 versus EUR 22.80.

Key points in brief

  • mwb research downgraded Stratec from Hold to Sell on September 17, 2026, keeping its EUR 21.00 price target.
  • Second-quarter 2026 revenue rose 2.40 percent to EUR 59.10 million, while adjusted EBIT margin reached 11.90 percent.
  • Stratec stock was at EUR 22.03 at Lang & Schwarz on October 8, 2026, versus the EUR 22.80 Xetra close on October 7.
3D-Architekturrendering eines modernen Medizintechnik-Firmengebäudes mit Glasfassade
Stratec SE (DE000STRA555) betreibt moderne Produktionsstätten, visualisiert als architektonisches Rendering eines Firmensitzes, Illustration mit AI erstellt.

Stratec (ISIN DE000STRA555) was trading at EUR 22.03 at Lang & Schwarz on October 8, 2026, versus the EUR 22.80 Xetra close on October 7. On September 17, 2026, mwb research downgraded Stratec from Hold to Sell while keeping its EUR 21.00 price target.

The downgrade rests on second-quarter figures

Stratec's second-quarter 2026 revenue increased 2.40 percent year over year at constant currency to EUR 59.10 million, according to mwb research in its September 17, 2026 analysis. Adjusted EBIT rose 125.30 percent year over year to EUR 7.00 million, lifting the adjusted EBIT margin to 11.90 percent.

The improvement was concentrated in the second quarter after a weak start to 2026. The main pressure point is execution: mwb research calculated that Stratec would need EUR 149 million to EUR 161 million of revenue in the second half of 2026, equal to 12.00 percent to 22.00 percent growth from the second half of 2025.

Three dated events shape the recovery

On August 14, 2026, Stratec reported second-quarter revenue of EUR 59.10 million and reported earnings per share of EUR 0.39, according to Makkler. On September 17, 2026, mwb research set its price target at EUR 21.00 and changed its rating from Hold to Sell. On September 30, 2026, Stratec listed a voting-rights notification, while fixed ownership stood at 40.38 percent, according to its stock information.

What does Q4 execution require?

The second-half requirement puts the final quarter at the center of the 2026 outlook. The next reported earnings date is November 12, 2026, with a consensus revenue estimate of EUR 59.00 million and an earnings-per-share estimate of EUR 0.23, according to Makkler.

Stratec stock trades below the Xetra close

At Lang & Schwarz, Stratec stock was trading at EUR 22.03 on October 8, 2026. That is minus 3.38 percent versus the EUR 22.80 Xetra close on October 7, 2026, calculated from the two euro prices. The further course of trading is shown by the continuously updated real-time quote of Stratec stock.

Stratec stock facts

  • Company: Stratec SE
  • ISIN: DE000STRA555
  • WKN: STRA55
  • Ticker: SBS
  • Primary exchange: Xetra
  • Price Lang & Schwarz as of October 8, 2026: EUR 22.03
  • Change versus Xetra close: minus 3.38 percent
  • Xetra close October 7, 2026: EUR 22.80
  • Market capitalization: EUR 277.2 million as of October 8, 2026
  • Sector / Industry: Healthcare / Medical Technology
  • Index membership: CDAX Prime All Share and DAXsubsector Medical Technology
  • Next earnings date: November 12, 2026

Market context: Market report DAX.

More news and analyses on Stratec stock

Disclaimer...

en | DE000STRA555 | STRATEC | boerse | 70269091 | bgmi